PharmTech Drug Digest 11.20
News|Articles|January 31, 2014

Eurofins MWG Operon Launches Ion Proton Sequencing Services

Author(s)Melanie Sena

Eurofins MWG Operon expands its exome sequencing services with the Ion Proton Next Generation Sequencer.

Eurofins MWG Operon has expanded its exome sequencing services with the Ion Proton Next Generation Sequencer.
Certification for Ion AmpliSeq Exome sequencing was also awarded after joining Life Technologies Corporation's Ion AmpliSeq Exome Certified Service Provider program (CSP). Using Life Technologies proprietary approach, consisting of the Ion AmpliSeq Exome Kit, the Ion Proton Sequencer and Ion Reporter Software, provides researchers with a fast, and cost-effective exome sequencing solution available with flexible throughput, according to the company.


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.